These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 12639726

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities.
    Traboulsee A, Dehmeshki J, Peters KR, Griffin CM, Brex PA, Silver N, Ciccarrelli O, Chard DT, Barker GJ, Thompson AJ, Miller DH.
    Mult Scler; 2003 Dec; 9(6):566-73. PubMed ID: 14664468
    [Abstract] [Full Text] [Related]

  • 4. Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.
    Sharma J, Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Munschauer FE, Bakshi R.
    AJNR Am J Neuroradiol; 2004 Dec; 25(6):985-96. PubMed ID: 15205136
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis.
    Zivadinov R, Grop A, Sharma J, Bratina A, Tjoa CW, Dwyer M, Zorzon M.
    J Neuroimaging; 2005 Jan; 15(1):27-36. PubMed ID: 15574571
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
    Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CR, Weiner HL.
    Arch Neurol; 2008 Nov; 65(11):1449-53. PubMed ID: 19001162
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis.
    Hemond CC, Chu R, Tummala S, Tauhid S, Healy BC, Bakshi R.
    Brain Behav; 2018 Aug; 8(8):e01068. PubMed ID: 30019857
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, Minagar A, Ukmar M, Benedetto Sy, Zorzon M.
    Int Rev Neurobiol; 2007 Aug; 79():521-35. PubMed ID: 17531857
    [Abstract] [Full Text] [Related]

  • 16. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis.
    Liptak Z, Berger AM, Sampat MP, Charil A, Felsovalyi O, Healy BC, Hildenbrand P, Khoury SJ, Weiner HL, Bakshi R, Guttmann CR.
    AJNR Am J Neuroradiol; 2008 Sep; 29(8):1465-70. PubMed ID: 18556361
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
    Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans-Coutinho M, Clanet M, Radue EW, Kappos L, European rIFN beta-1a in Relapsing MS Dose Comparison Trial Study Group.
    Arch Neurol; 2003 Dec; 60(12):1736-9. PubMed ID: 14676048
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.